LQDA Trading Analysis - 10/23/2026 03:12 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge of Liquidia Corporation (LQDA) and are provided as contextual background only, separate from the data-driven analysis below.

• LQDA received FDA approval for Yutrepia (treprostinil) inhalation powder in late 2025, expanding its pulmonary arterial hypertension portfolio and serving as a major fundamental catalyst.
• In early October 2026, a large one-day volume spike and sharp drop (Sept 30 close at $30.25 from $71.93 high) coincided with a competitor patent ruling or settlement uncertainty, per general biotech sector memory.
• Mid-October 2026 saw renewed upside with Oct 14 volume of 18.6M shares and close at $33.84, possibly on positive prescription or launch traction news.
• No confirmed near-term earnings date in provided data; fiscal year end was Dec 2025 per fundamentals.
• Headlines suggest a recovery narrative from the Sept 30 crash, aligning with the strong options call flow and recent price climb to $41.72 in minute data.

Fundamental Analysis

Based strictly on the embedded FUNDAMENTALS data for LQDA as of 2026-10-23:

• Trailing P/E is 23.20 with trailing EPS of 1.57; no forward P/E, PEG, or revenue metrics provided (all null).
• Market cap is 3.74B with 89.51M shares outstanding; dividend yield 0.00% (no dividend).
• Beta is 1.15 (moderate market sensitivity); institutional ownership 43.01%.
• 52-week range: high 93.61, low 21.94; current price near 39.47 is well below annual high.
• Historical volatility is 264.70% (extreme); average volume 7.12M.
• Profit margins, ROE, debt/equity, free cash flow, and revenue growth are null — not available in data.
• Analyst target mean price and consensus are null; no sell-side context provided.
• Fundamentals show a profitable but volatile small-cap biotech (P/E 23.20, EPS 1.57) with no growth metrics; this diverges from the sharp technical rebound and bullish options flow post-Sept crash.

Current Market Position

From daily and minute bars: The 2026-10-22 close was 39.47 (high 40.08, low 38.22, volume 2.55M). The 2026-10-23 minute data shows 14:30 bar open 39.86, high 41.73, low 38.69, close 41.66 on 2.03M volume, then 14:40 close 41.73. Recent daily closes rose from 30.25 (Sept 30) to 39.47 (Oct 22). Intraday momentum on Oct 23 is strongly up, with last 3 bars at 41.66–41.73 and volume surges at 14:30 (2.03M) and 15:55 (240K).

Technical Analysis

Price is above SMA 5 (36.60) and SMA 20 (37.06) but far below SMA 50 (56.53) — no golden cross, bearish long-term structure. RSI 77.24 is overbought. MACD -6.67 below signal -5.34, histogram -1.33 (bearish momentum despite price up). Bollinger mid 37.06, price 39.47 inside bands, no squeeze. 30-day range: price 39.47 is 31% up from low 22.31, 47% below high 74.74.

True Sentiment Analysis (Delta 40-60 Options)

From LQDA_options_20261023 data: Sentiment is Bullish. Call dollar volume 1,326,335 (92.2%), put 111,470 (7.8%), total 1,437,805. Contracts: calls 1,521 vs puts 111. Pure directional conviction heavily call-sided.

Options flow shows strong bullish near-term expectation, diverging from MACD bearish and SMA 50 distance. Spread recommender noted: "Divergence detected between technical indicators and options sentiment."

Key Price Levels (Observational Only)